Clinical Trials Logo

Metaplasia clinical trials

View clinical trials related to Metaplasia.

Filter by:

NCT ID: NCT03672708 Not yet recruiting - Clinical trials for Gastric Intestinal Metaplasia

Confocal Laser Endomicroscopy With Cresyl Violet for in Vivo Diagnosis of Gastric Intestinal Metaplasia

Start date: September 16, 2018
Phase: N/A
Study type: Interventional

Confocal laser endomicroscopy (CLE) is a novel endoscopic system which can provide approximately 1000-fold magnification of the gastrointestinal mucosa. Previous studies have demonstrated its diagnostic value for Gastric intestinal metaplasia (GIM) with the use of a contrast agent.Recently, Cresyl violet (CV) has been used in CLE to visualize tissue architecture in human ileum, colon or myenteric plexus.No investigation has reported the characterization of GIM imaged with CLE when using CV as staining dye

NCT ID: NCT03670134 Not yet recruiting - Barrett Esophagus Clinical Trials

Predict Recurrence of Barrett's Esophagus After Complete Eradication of Intestinal Metaplasia

Start date: December 1, 2018
Phase: N/A
Study type: Interventional

Researchers are trying to see if the Nvision® Imaging System (VLE) can accurately determine the risk of recurrent Barrett's esophagus in patients with Barrett's esophagus which have been clear of disease.

NCT ID: NCT03554356 Active, not recruiting - Barrett Esophagus Clinical Trials

Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)

NO FEAR-BE
Start date: September 4, 2018
Phase: N/A
Study type: Interventional

A multicenter, prospective, single arm, non randomized clinical trial to evaluate the safety and efficacy of the C2 CryoBalloon Focal Ablation System (CbFAS) for the treatment of persistent dysplasia or intestinal metaplasia (IM) in the tubular esophagus after 3 or more radiofrequency ablations (RFA) for dysplastic BE, or <50% eradication of Barrett's Esophagus (BE) after 2 RFA treatments.

NCT ID: NCT03380052 Recruiting - Stomach Neoplasms Clinical Trials

OLGA and OLGIM Stage System for Gastric Cancer

Start date: February 2006
Phase: N/A
Study type: Observational

To validate OLGA and OLGIM staging system for estimating GC risk according to Lauren's histologic classification in South Korea. Also attempted to estimate synergistic interaction among the several risk factors to help establish surveillance strategy.

NCT ID: NCT03285906 Recruiting - Clinical trials for Esophagus Cancer, Stage III

An Exploratory Clinical Study of Apatinib for the 2nd Treatment of Esophageal Cancer or Esophageal and Gastric

Start date: March 1, 2017
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this Phase II, Open-label, single arm, exploratory study is to evaluate the efficacy and the safety of Apatinib(500mg/d)for the second - line treatment of esophageal cancer or esophageal and gastric

NCT ID: NCT03250091 Recruiting - Gastric Cancer Clinical Trials

Surveillance of Patients With Precancerous Lesions of the Stomach

Start date: June 19, 2017
Phase:
Study type: Observational

The project will aim to identify and determine subgroups of patients with different risks of progression to gastric cancer and to assess appropriate follow-up intervals. Implementing risk stratification only high risk individuals will be offered and performed endoscopic surveillance.

NCT ID: NCT03228095 Enrolling by invitation - Colorectal Cancer Clinical Trials

Volatiles in Breath and Headspace Analysis - Diagnostic Markers

Volatolome
Start date: July 24, 2017
Phase:
Study type: Observational

Detection of Volatile Organic Compounds (VOC) directly from tissue by headspace analysis (skin, surgery material, other tissue) and exhaled breath is feasible using affordable user-friendly novel nano-chemo sensors that can accurately be used for screening and monitoring purpose

NCT ID: NCT03188406 Recruiting - Gastric Cancer Clinical Trials

Gastric Cancer Precursor Lesions (GCPL) Study

Start date: December 14, 2018
Phase:
Study type: Observational

Background: Gastric cancer is a leading cause of cancer deaths around the world. It is a serious problem in places like East Asia, Central and South America, and Eastern Europe. Researchers want to study the causes of gastric cancer. They want to reduce the number of people with stomach cancer. Objectives: To learn more about bacteria factors and other causes of gastric cancer. To study potential markers associated with precancer gastric lesions. Eligibility: Adults ages 40-70 at certain hospitals in Chile who: Are going to have endoscopies OR have stomach cancer and need surgery Design: Participants will give tissue samples about the size of a grain of rice. Some participants will donate a portion of the stomach tissue that is removed as part of their clinical care. Participants will give access to reports of their stomach exam. They will allow researchers to photograph the microscope slides of their tissue samples. Participants will answer questions. The topics of the questions include: Age, height, weight, ethnicity Education Habits including tobacco and alcohol Personal and family history of disease Reproductive history Diet Some participants will give blood, urine, saliva, and stool samples. Study staff will collect the blood. They will tell the participants how to collect the other samples themselves.

NCT ID: NCT02933229 Not yet recruiting - Helicobacter Pylori Clinical Trials

The Influence of Helicobacter Pylori Eradication on Gastric Pathology: a Long-term, Prospective Cohort Study

Start date: October 2016
Phase: Phase 4
Study type: Interventional

Helicobacter pylori (H. pylori) infection, affecting an estimated 50% of the global population, is a main cause of chronic gastritis, peptic ulcers and gastric cancer. By causing progressive damage to the stomach and may eventually result in gastric atrophy, H. pylori infection has been demonstrated to be responsible for more than 95% of gastric malignancies

NCT ID: NCT02932735 Not yet recruiting - Clinical trials for the Operative Link on Gastric Intestinal Metaplasia

The Efficacy of Probe-based Confocal Laser Endomicroscopy in Staging OLGIM

Start date: October 2016
Phase: N/A
Study type: Observational

Gastric intestinal metaplasia (GIM) is an important premalignant lesion for gastric cancer. Precisely surveillance of patients with GIM may result in early detection and improved prognosis. Though important, it is not necessary to recommend surveillance endoscopy for all patients with GIM, since the progression rate to gastric cancer within 10 years is only 1.8% in those patients.